All Pharma News
price-trendAsk Us
AbbVie pens $2B+ next-gen psychedelic pact with Gilgamesh

AbbVie pens $2B+ next-gen psychedelic pact with Gilgamesh
Gabrielle Masson FIERCE BIOTECH
14 May 2024
Share Share
AbbVie, Gilgamesh Collaborate On Next-Gen Psychiatric Therapies

AbbVie, Gilgamesh Collaborate On Next-Gen Psychiatric Therapies
PR NEWSWIRE
13 May 2024
Share Share
Gilgamesh Initiates GM-1020 Phase 2a In Depression

Gilgamesh Initiates GM-1020 Phase 2a In Depression
PR NEWSWIRE
01 May 2024
Share Share
Gilgamesh Pharma Awarded $14 Million National Institute on Drug Abuse Grant

Gilgamesh Pharma Awarded $14 Million National Institute on Drug Abuse Grant
PR NEWSWIRE
14 Mar 2024
Share Share
Gilgamesh Successfully Completes Phase 1 SAD/MAD Clinical Trials of GM-1020

Gilgamesh Successfully Completes Phase 1 SAD/MAD Clinical Trials of GM-1020
PR NEWSWIRE
21 Sep 2023
Share Share